Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors), PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC24H26N4O3 |
InChIKeyCTLOSZHDGZLOQE-UHFFFAOYSA-N |
CAS Registry916574-83-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Phase 2 | US | 29 Sep 2013 | |
Mantle-Cell Lymphoma | Phase 2 | BE | 01 May 2011 | |
Mantle-Cell Lymphoma | Phase 2 | FR | 01 May 2011 | |
Advanced Malignant Solid Neoplasm | Phase 2 | GB | 01 Jun 2009 | |
Advanced Malignant Solid Neoplasm | Phase 2 | FR | 01 Jun 2009 | |
Non-Small Cell Lung Cancer | Phase 2 | US | - | |
Non-Small Cell Lung Cancer | Phase 2 | US | - | |
Non-Small Cell Lung Cancer | Phase 2 | - | - | |
Non-Small Cell Lung Cancer | Phase 2 | - | - | |
Ovarian Cancer | Phase 2 | - | - |
Phase 1/2 | 45 | (CEP-9722 Dose 1 QD) | qkaoacijlm(vrjzelxocb) = ytklachbhu ijkuludojm (ukfdckvety, dfsukngkmd - ukjwtggatg) View more | - | 30 Jan 2024 | ||
(CEP-9722 Dose 1 BID) | qkaoacijlm(vrjzelxocb) = wptqssjenc ijkuludojm (ukfdckvety, pkbzxkdyoz - wfsczrwefh) View more |